April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
Evaluation of Functional Visual Performance Using the IVAD Method With Currently Marketed Artificial Tear Products
Author Affiliations & Notes
  • G. Torkildsen
    Ora, Andover, Massachusetts
  • M. T. Christensen
    Alcon Research LTD, Ft Worth, Texas
  • A. E. Martin
    Alcon Research LTD, Ft Worth, Texas
  • M. Tudor
    Alcon Research LTD, Ft Worth, Texas
  • J. Griffin
    Alcon Research LTD, Ft Worth, Texas
  • G. W. Ousler, III
    Ora, Andover, Massachusetts
  • D. Welch
    Ora, Andover, Massachusetts
  • M. B. Abelson
    Ora, Andover, Massachusetts
    Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  G. Torkildsen, Ora, C; M.T. Christensen, Alcon, E; A.E. Martin, Alcon, E; M. Tudor, Alcon, E; J. Griffin, Alcon, E; G.W. Ousler, III, Ora, E; D. Welch, Ora, E; M.B. Abelson, Ora, E.
  • Footnotes
    Support  Alcon Research LTD
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 4649. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. Torkildsen, M. T. Christensen, A. E. Martin, M. Tudor, J. Griffin, G. W. Ousler, III, D. Welch, M. B. Abelson; Evaluation of Functional Visual Performance Using the IVAD Method With Currently Marketed Artificial Tear Products. Invest. Ophthalmol. Vis. Sci. 2009;50(13):4649.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : The purpose of this study was to evaluate functional visual acuity as determined by the interblink interval visual acuity decay (IVAD) test with two marketed artificial tear products.

Methods: : This was a controlled, randomized, double masked, two-period crossover study comparing a PEG/PG based (SYSTANE® Ultra, Alcon) and a CMC/Glycerin based tear (OptiveTM, Allergan). 48 dry eye patients received both products in a randomized fashion with a 7-day washout between periods. Baseline measurements of IVAD, recorded as time (sec) that the patient could maintain best corrected visual acuity (BCVA) within an interblink period were performed. Following a single drop, IVAD measurements were repeated at 15, 45 and 90 min. Data was evaluated using a right-censored survival analysis with significance determined by Wilcoxon (p < 0.05).

Results: : In dry eye patients, the PEG/PG based tear showed a statistically significant increase in the length of time at best corrected visual acuity within an interblink period at 90 minutes post instillation when compared to the CMC/Glycerin based tear (p=.0365). Baseline values were similar for both arms with median times at BCVA of 5.78 and 5.77 for the PEG/PG and CMC/Glycerin tears, respectively. The median times of BCVA measured at 15 (7.75 sec and 6.42 sec) and 45 (6.46 sec and 5.41 sec) minutes post instillation for PEG/PG and CMC/Glycerin, respectively, were not statistically different between groups. 90 minutes post-instillation, the PEG/PG tear showed significant improvement of time at BCVA with a median time of 9.17 sec compared to 6.85 sec for the CMC/Glycerin tear.

Conclusions: : This study measured visual decay within the interblink period simulating routine visual tasking under focused conditions like reading, working on a computer or driving a car. The tear containing PEG/PG demonstrated a significant improvement in quality of vision in dry eye patients 90 minutes following a single drop. This tear allowed a 58% increase in time at BCVA within the interblink period compared to baseline and was significantly longer (33%) than the CMC/Glycerin product at the 90 minute timepoint.

Clinical Trial: : www.clinicaltrials.gov NCT00673764

Keywords: cornea: tears/tear film/dry eye • cornea: clinical science • visual acuity 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.